Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/05—Phenols
  • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/06—Antibacterial agents for tuberculosis

Definitions

• the present invention relates to the use of AZD2563 in the treatment of tuberculosis.
• Tuberculosis is a disease caused by Mycobacterium tuberculosis (Mtu), which in 1990 was declared a global epidemic by the World Health Organisation (WHO). It affects more than one third of the world's population resulting in 8 million new patients and 2 million deaths every year. Also there exists a scenario called “Latent TB", which occurs when germs remain in the body in a quiescent state but without any apparent effect on the health of the individual. In many cases this stage may last for many years or decades. In case of normal human being the chance of activation is 2-23% in a lifetime. However in case of immuno-compromised patients (like HIV) the chances of activation rise to 10 % every year.
• the current treatment of drug sensitive tuberculosis is at least six months long and requires a combination of isoniazid, rifampicin, pyrazinamide and ethambutol in the first two months followed by isoniazid and rifampicin for a period of four months.
• drug resistance to these drugs has increased and the last of drugs for tuberculosis was introduced into clinical practice in the late 1960's.
• the evolution of resistance could result in strains against which currently available antitubercular agents will be ineffective and treatment in such cases may last two years with no guarantee of cure. So there is an urgent need to introduce new drugs particularly those with either a novel mechanism of action and/or containing new pharmacophoric groups and new treatment regimens to overcome not only rising drug resistance but also improve the overall treatment duration.
• the compound can form stable acid or basic salts, and in such cases administration of a compound as a salt may be appropriate, and pharmaceutically acceptable salts may be made by conventional methods such as those described following.
• Suitable pharmaceutically-acceptable salts include acid addition salts such as methanesulfonate, tosylate, ⁇ -glycerophosphate. fumarate, hydrochloride, citrate, maleate, tartrate and hydrobromide. Also suitable are salts formed with phosphoric and sulfuric acid.
• suitable salts are base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine, tris-(2-hydroxyethyl)amine, N-methyl d-glucamine and amino acids such as lysine.
• the pharmaceutically-acceptable salt is the sodium salt.
• salts which are less soluble in the chosen solvent may be utilised whether pharmaceutically acceptable or not.
• the compound or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.
• the formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein. The same applies to compound names.
• the present invention encompasses any racemic, optically-active, polymorphic or stereoisomeric form, or mixtures thereof, at any additional asymmetrically substituted carbon(s) and sulphur atom(s), which possesses anti-tubercular properties
• Optically-active forms may be prepared by procedures known in the art for example, by resolution of the racemic form by re-crystallisation techniques, by synthesis from optically-active starting materials, by chiral synthesis, by enzymatic resolution, by biotransformation, or by chromatographic separation using a chiral stationary phase.
• the compound may exhibit polymorphism. It is to be understood that the present invention encompasses any polymorphic form, or mixtures thereof, which form possesses which possesses anti-tubercular properties
• the compound of the invention and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses the use of all such solvated forms, which possesses anti-tubercular properties.
• Our investigations have shown AZD2563 can act as an anti-tubercular agent for a longer time with lower exposure when compared with linezolid. This may allow once daily dosing, whereas linezolid is dosed twice a day. Whilst we do not wish to be bound by theoretical considerations this may provide an improved safety profile.
• AZD2563 or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof in the preparation of a medicament for use in the treatment of Mycobacterium tuberculosis.
• Mycobacterium tuberculosis which method comprises contacting cells infected by Mycobacterium tuberculosis with a pharmaceutically effective amount of AZD2563 or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof whereby the cells are attenuated.
• a method for the treatment of Mycobacterium tuberculosis comprises administering a therapeutically effective amount of AZD2563 or a pharmaceutically-acceptable salt, or an in-vivo- hydrolysable ester thereof to a patient in need of anti-tubercular therapy.
• a pharmaceutical formulation comprising (5R)-3-[4-[l-[(2S)-2,3-dihydroxypropanoyl]-3,6-dihydro-2H-pyridin-4-yl]-3,5- difluoro-phenyl]-5-(isoxazol-3-yloxymethyl)oxazolidin-2-one or a pharmaceutically- acceptable salt, or an in-vivo-hydrolysable ester thereof, for administration no more than once daily.
• AZD2563 may be used for both human and animal therapy. Each represents an independent aspect of the invention.
• the compound of the invention described herein may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. Where the administration is sequential or separate, the delay in administering the second component should not be such as to lose the beneficial effect of the combination.
• Suitable classes and substances may be selected from one or more of the following: i) other antibacterial agents for example macrolides e.g. erythromycin, azithromycin capreomycin or clarithromycin; quinolones e.g. ciprofloxacin or levofloxacin; ⁇ -lactams e.g. penicillins e.g.
• amoxicillin or piperacillin cephalosporins e.g. ceftriaxone or ceftazidime
• carbapenems e.g. meropenem or imipenem etc
• aminoglycosides e.g. gentamicin or tobramycin; or oxazolidinones
• anti-infective agents for example, an antifungal triazole e.g.
• iii) biological protein therapeutics for example antibodies, cytokines, bactericidal/permeability-increasing protein (BPI) products; and/or iv) one or more antibacterial agents useful in the treatment of tuberculosis such as one or more of rifampicin, isoniazid, pyrazinamide, ethambutol, quinolones e.g. moxifloxacin or gatifloxacin, streptomycin, cycloserine, ethionamide, thiacetazone, p- aminosalicylic acid (PAS), amikacin, kanamycin, clofazimine .
• biological protein therapeutics for example antibodies, cytokines, bactericidal/permeability-increasing protein (BPI) products
• BPI bactericidal/permeability-increasing protein
• one or more antibacterial agents useful in the treatment of tuberculosis such as one or more of
• v) efflux pump inhibitors comprising (5R)-3-[4-[l-[(2S)-2,3-dihydroxypropanoyl]-3,6-dihydro-2H-pyridin-4-yl]-3,5- difluoro-phenyl]-5-(isoxazol-3-yloxymethyl)oxazolidin-2-one, or a pharmaceutically acceptable salt thereof in combination with a chemotherapeutic agent selected from: i) one or more additional antibacterial agents; and/or ii) one or more anti-infective agents; and/or iii) biological protein therapeutics for example antibodies, cytokines, bactericidal/permeability-increasing protein (BPI) products; iv) one or more antibacterial agents useful in the treatment of tuberculosis and/or v) one or more efflux pump inhibitors.
• a chemotherapeutic agent selected from: i) one or more additional antibacterial agents; and/or ii)
• the combination therapy is provided for administration no more than once daily.
• Biological testing procedures Bacterial Susceptibility Testing Methods
• the compound may be tested for antimicrobial activity by susceptibility testing in liquid media.
• Compounds may be dissolved in dimethylsulfoxide and tested in 10 doubling dilutions in the susceptibility assays.
• the organisms used in the assay may be grown overnight on suitable agar media and then suspended in a liquid medium appropriate for the growth of the organism.
• the suspension can be a 0.5 McFarland and a further 1 in 10 dilution can be made into the same liquid medium to prepare the final organism suspension in 100 ⁇ L. Plates can be incubated under appropriate conditions at 37 °C for 24 hrs prior to reading.
• the Minimum Inhibitory Concentration (MIC) may be determined as the lowest drug concentration able to reduce growth by 90% or more.
• Protocol for MIC testing Microplate Alamar Blue Assay (Franzblau et al, 1998.
• the MIC was defined as the lowest drug concentration, which prevented a colour change from blue to pink.
• MBC minimum bactericidal concentration
• Bone Marrow Derived Macrophages (BMDM) culture and Infection Bone marrow derived macrophages were obtained from BALB/c mice. Mice were euthanized by exposure to CO 2 and the femur and tibia were dissected out. The bones were trimmed at each end and the marrow was flushed out with cold RPMI 1640 medium using 26-gauge needle. Cell suspensions were then washed twice with medium and plated at 2x10 6 cells/ml in 24 well plates in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 20% culture supernatant of L929 (mouse fibroblast cell line). The cells were incubated at 37°C in 5% CO 2 for 7days with twice medium change.
• FBS fetal bovine serum
• Macrophages were used for infection with Mtu on 8 th day of culture. They were infected with MOI of 1 :10 (macrophage: bacteria) for 2 hours in the regular culture conditions. After 2 hours the monolayers were thoroughly washed with pre-warmed Phosphate buffered Saline twice, to remove any extra cellular bacteria and replaced with RPMI 1640 with all the supplements containing drugs of different concentrations. (0.5 to 8 mg/L). The plates containing cells were periodically observed to note any changes in the cell morphology (due to drug toxicity) or lysis of monolayer. After 10 days of drug exposure (post infection) the monolayers were gently washed and lysed with 0.04% SDS and plated onto nutrient 7Hl 1 agar. Bacterial colony formation was enumerated after incubation of plates for 21 days at 37° C, 5% CO 2 in humidified atmosphere. Data were expressed as the mean Log 10 mean CFU for each drug concentration and the entire experiment was repeated twice.
• mice were infected in a biosafety level 3 facility via the inhalation route in an aerosol infection chamber.
• BALB/c mice (8-10 week old) were infected via respiratory route to achieve 100-200 bacilli/animal on the day of infection.
• the mice were dosed once per day orally 100-125 mg/kg of body weight, with therapy given 6 days a week for 4 weeks.
• mice were killed by exposure to CO 2 , and the lungs were aseptically removed for homogenization in a final volume of 3 ml by using Wheaton Teflon-Glass tissue grinders (catalogue no. W012576). Each suspension was serially diluted in 10-fold steps, and at least 3 dilutions were plated onto Middlebrook 7Hl 1 agar supplemented with 10% albumin dextrose catalase (Difco Laboratories) and incubated at 37°C with 5% CO 2 for 3 weeks. The plates are enumerated for colony forming units (CFU) and the effect is compared against no treatment control.
• CFU colony forming units
• BALB/c mice (8-10 week old) were dosed with the compound in an appropriate vehicle at specified doses as a single dose at a dose volume of 10mL/Kg.
• the dose was administered either orally or parentally.
• Blood samples were collected at various time points ranging from 0.08h to 5Oh post dosing and plasma harvested by acceptable methods like precipitation or extraction.
• the concentration of the compound in plasma was determined by standard analytical instruments like HPLC and/or LC-MS.
• PK analyses of the plasma concentration-time relationships were performed with WinNonLin software (or any other suitable software program) .
• a noncompartmental analysis program was used to calculate the PK parameters, such as the maximum concentration of drug in plasma (C max ), time to C ma ⁇ (t ma ⁇ ), elimination rate constant, elimination half- life, and AUC from time zero to infinity (AUC o-mf)
• AZD2563 was tested in the above-mentioned assays and the following results obtained:
• Table 1 Comparison of Microbiological Activities for AZD2563 and Linezolid.
• AZD 2563 has greater bactericidal activity in the intracellular infection model (BMDM) as compared to Linezolid. Comparing the PK/PD indices in efficacy experiments, we see that, at the minimum effective dose, AZD2563 gives much lower exposure and requires lower fAUC/MIC but still yields similar potency when compared to Linezolid.
• Table 2 Comparison of PK Properties for AZD2563 and Linezolid in various Species.
• the compounds were dosed to animals at various doses (not exceeding 25mg/kg) and the concentration of the compound at various time points was estimated.
• the data was analysed and PK parameters like AUC. Xy 2 and fAUC/MIC were estimated and the data shown in the table above. From the data the PK parameters such as longer tl/2 and lower exposure seem to hold in all the species and hence similar conclusions regarding toxicity and dosing intervals can be made in various species.

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=42262301

Family Applications (1)

Country Status (17)

Citations (3)

Family Cites Families (1)

• 2010
  • 2010-03-15 UY UY0001032493A patent/UY32493A/es not_active Application Discontinuation
  • 2010-03-15 TW TW099107448A patent/TW201036609A/zh unknown
  • 2010-03-16 KR KR1020117021496A patent/KR20110127219A/ko not_active Application Discontinuation
  • 2010-03-16 WO PCT/GB2010/050445 patent/WO2010106355A1/en active Application Filing
  • 2010-03-16 EA EA201101328A patent/EA201101328A1/ru unknown
  • 2010-03-16 BR BRPI1009510A patent/BRPI1009510A2/pt not_active Application Discontinuation
  • 2010-03-16 MX MX2011009263A patent/MX2011009263A/es unknown
  • 2010-03-16 CN CN2010800119557A patent/CN102355901A/zh active Pending
  • 2010-03-16 JP JP2012500313A patent/JP2012520864A/ja active Pending
  • 2010-03-16 EP EP10710617A patent/EP2408452A1/en not_active Withdrawn
  • 2010-03-16 AR ARP100100833A patent/AR075861A1/es unknown
  • 2010-03-16 AU AU2010224619A patent/AU2010224619A1/en not_active Abandoned
  • 2010-03-16 CA CA2755209A patent/CA2755209A1/en not_active Abandoned
  • 2010-03-16 US US13/256,658 patent/US20120035219A1/en not_active Abandoned
  • 2010-03-16 SG SG2011059847A patent/SG173770A1/en unknown
• 2011
  • 2011-08-18 IL IL214715A patent/IL214715A0/en unknown
  • 2011-10-14 ZA ZA2011/07562A patent/ZA201107562B/en unknown

Patent Citations (3)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events